Literature DB >> 7605156

Distribution of CD4+ T lymphocytes at diagnosis of acquired immunodeficiency syndrome-defining and other human immunodeficiency virus-related illnesses. The Adult and Adolescent Spectrum of HIV Disease Project Group.

D L Hanson1, S Y Chu, K M Farizo, J W Ward.   

Abstract

BACKGROUND: Depletion of circulating CD4+ T lymphocytes among persons infected with the human immunodeficiency virus (HIV) is associated with increased risk for development of opportunistic, life-threatening diseases and death.
METHODS: To describe the levels of CD4+ T lymphocytes at which acquired immunodeficiency syndrome (AIDS)-defining and other illnesses initially occur, we analyzed data from an ongoing survey of medical records of 18,062 HIV-infected patients who received medical care between January 1990 and August 1993 in more than 100 clinics, hospitals, and private practices in 10 US cities. We report the median and upper 80th percentile CD4+ T-lymphocyte counts at diagnosis.
RESULTS: We found that AIDS-defining conditions first occurred in HIV-infected patients with CD4+ T-lymphocyte counts below 0.20 x 10(9)/L (200/microL) for 80% of diagnoses. Similarly, AIDS-defining diseases occurred at counts below 0.05 x 10(9)/L for 50% of diagnoses. Exceptions to both criteria were invasive cervical cancer and pulmonary tuberculosis. Non-AIDS-defining illnesses with which 80% of patients were diagnosed at CD4+ T-lymphocyte counts below 0.20 x 10(9)/L were bacterial sepsis and retinopathy (excluding cytomegalovirus).
CONCLUSION: Our observations support the need for continued CD4+ cell count monitoring below a level of 0.20 x 10(9)/L as a guide to diagnosis and medical management of HIV-infected persons.

Entities:  

Mesh:

Year:  1995        PMID: 7605156

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  19 in total

1.  Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting?

Authors:  April C Pettit; Cathy A Jenkins; Samuel E Stinnette; Peter F Rebeiro; Robert B Blackwell; Stephen P Raffanti; Bryan E Shepherd; Timothy R Sterling
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-01       Impact factor: 3.731

Review 2.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

3.  CDC staging based on absolute CD4 count and CD4 percentage in an HIV-1-infected Indian population: treatment implications.

Authors:  M Vajpayee; S Kaushik; V Sreenivas; N Wig; P Seth
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

4.  Effect of tuberculosis preventive therapy on HIV disease progression and survival in HIV-infected adults.

Authors:  Hyun J Lim; Alphonse Okwera; Harriet Mayanja-Kizza; Jerrold J Ellner; Roy D Mugerwa; Christopher C Whalen
Journal:  HIV Clin Trials       Date:  2006 Jul-Aug

Review 5.  Animal models to study Mycobacterium tuberculosis and HIV co-infection.

Authors:  Ming Guo; Wen-Zhe Ho
Journal:  Dongwuxue Yanjiu       Date:  2014-05

6.  Evaluation of the status of tuberculosis as part of the clinical case definition of AIDS in India.

Authors:  V S S Attili; V P Singh; M Rai; D V Varma; S Sundar
Journal:  Postgrad Med J       Date:  2005-06       Impact factor: 2.401

7.  Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease.

Authors:  Christine M Rousseau; Ruth W Nduati; Barbra A Richardson; Matthew S Steele; Grace C John-Stewart; Dorothy A Mbori-Ngacha; Joan K Kreiss; Julie Overbaugh
Journal:  J Infect Dis       Date:  2003-02-18       Impact factor: 5.226

8.  Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load.

Authors:  Collin R Diedrich; Joshua T Mattila; Edwin Klein; Chris Janssen; Jiayao Phuah; Timothy J Sturgeon; Ronald C Montelaro; Philana Ling Lin; Joanne L Flynn
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

9.  Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.

Authors:  Amanda Mocroft; Jonathan A C Sterne; Matthias Egger; Margaret May; Sophie Grabar; Hansjakob Furrer; Caroline Sabin; Gerd Fatkenheuer; Amy Justice; Peter Reiss; Antonella d'Arminio Monforte; John Gill; Robert Hogg; Fabrice Bonnet; Mari Kitahata; Schlomo Staszewski; Jordi Casabona; Ross Harris; Michael Saag
Journal:  Clin Infect Dis       Date:  2009-04-15       Impact factor: 9.079

10.  CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South Africa.

Authors:  Christopher J Hoffmann; Michael Schomaker; Matthew P Fox; Portia Mutevedzi; Janet Giddy; Hans Prozesky; Robin Wood; Daniela B Garone; Matthias Egger; Andrew Boulle
Journal:  J Acquir Immune Defic Syndr       Date:  2013-05-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.